|Day Low/High||86.92 / 89.79|
|52 Wk Low/High||77.50 / 125.86|
Jim Cramer talks about the Fed, and outlines your game plan.
Jim Cramer weighs in on Qualcomm, Momo, Ciena, AbbVie, LM Ericsson and more.
Jim Cramer says a trade deal could help, but what matters after today is earnings -- and how bad the shortfalls will be.
And it is happening not a moment too soon.
- Initiation of clinical studies with TTX-030 is targeted in Q1 2019
Dow Theory presents tips for surviving a bear market, some top year-end stock bargains and a simple strategy for monthly income.
ABBV offers an ideal mix of growth, value and income.
- Regulatory applications supported by robust SELECT Phase 3 program evaluating more than 4,000 patients with moderate to severe rheumatoid arthritis[1-5]
As cannabis becomes more and more legal, investors have started to wonder what that means for them.
- Independent Data Monitoring Committee responsible for ongoing review of study data recommended enrollment be stopped
- Results from this interim analysis showed ibrutinib plus rituximab prolonged progression-free survival (PFS) compared to a standard chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab (FCR) at nearly 3 years of follow-up (abstract #LBA-4)
- These data were included in the recent sNDA accepted by the U.S. FDA, which received Priority Review, and could lead to the first chemotherapy-free anti-CD20 combination approved for first-line CLL treatment
- With up to seven years of treatment, sustained PFS rates with ibrutinib in CLL/small lymphocytic lymphoma (SLL) at 80 percent for previously untreated patients
- The data demonstrated that VENCLEXTA®/VENCLYXTO® in combination with rituximab (VenR) reduced the risk of disease progression or death compared to a standard of care, bendamustine plus rituximab (BR), after a median three-year follow-up
- Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for patients who are ineligible for intensive chemotherapy[1,2]
- AbbVie will present nearly 40 abstracts featuring data from approved and investigational medicines
-Elagolix, in combination with add-back therapy, achieved statistically significant reduction in heavy menstrual bleeding associated with uterine fibroids compared to placebo
- EXPEDITION-8 is the first Phase 3b study evaluating 8 weeks of MAVYRET™ in treatment-naïve chronic hepatitis C virus (HCV)-infected patients with compensated cirrhosis across all major genotypes (GT1-6)
SAN FRANCISCO, Nov. 9, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors in AbbVie Inc.
- New MappingHepC.com website provides HCV community an easily accessible source of chronic HCV epidemiology data
NEW YORK, Nov. 7, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AbbVie Inc.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.